Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Capital Expenditures (2024 - 2025)

Historic Capital Expenditures for Prelude Therapeutics (PRLD) over the last 2 years, with Q2 2025 value amounting to $20000.0.

  • Prelude Therapeutics' Capital Expenditures fell 9442.9% to $20000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $120000.0, marking a year-over-year change of. This contributed to the annual value of $764000.0 for FY2024, which is 7825.22% down from last year.
  • As of Q2 2025, Prelude Therapeutics' Capital Expenditures stood at $20000.0, which was down 9442.9% from $47000.0 recorded in Q1 2025.
  • Over the past 5 years, Prelude Therapeutics' Capital Expenditures peaked at $359000.0 during Q2 2024, and registered a low of $20000.0 during Q2 2025.